Navigation Links
Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
Date:1/30/2013

HAYWARD, Calif., Jan. 30, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced that it has completed the previously announced underwritten public offering of 60,606,061 shares of its common stock, offered at a price of $0.66 per share.  In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 9,090,909 shares.  The gross proceeds to the Company from the sale of shares in this offering, before deducting customary underwriting discounts and commissions, were $40.0 million.  Anthera intends to use the net proceeds from this offering for general corporate purposes. 

Jefferies & Company, Inc. is acting as sole book-running manager in the offering and Leerink Swann LLC is acting as co-manager.  Trout Capital LLC has acted as an advisor to the Company.

The securities described above were offered by the Company pursuant to a shelf registration statement previously filed with, and declared effective by, the Securities and Exchange Commission (the "SEC").  A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov.  Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements about the Company's expectations with respect to its public offering, including statements about its intended use of proceeds from the offering.  Such statements are based on the Company's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to  those set forth in the Company's public filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.  The Company disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
2. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
3. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
4. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
5. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
6. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
7. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
8. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
9. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
10. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
11. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... JOSE, Calif. , Feb. 21, 2017 Cadence ... that its Cadence ® Tensilica ® Fusion F1 ... ™ MAC IP offering. The licensable IP targets SoCs ... city and industrial applications. M2B leveraged the Fusion F1 DSP ... run value-added applications like voice trigger, audio identification and sensor ...
(Date:2/21/2017)... Research and Markets has announced the addition of the "Liver Cirrhosis ... ... Cirrhosis Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... answers the following questions: What are the key ... positioned in the Global Liver Cirrhosis market? What are ...
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets has ... - 2016" report to their offering. ... The latest research Rosacea Drugs Price Analysis and Strategies ... market. The research answers the following questions: ... attributes? How are they positioned in the Global Rosacea market? ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... As recently as 2015, rhinoplasty was ... American Society of Plastic Surgeons. Some patients want to make a change in the ... and improve their breathing ability. The team at usrhinoplasty.org is expanding its ...
(Date:2/21/2017)... ... February 21, 2017 , ... Ray Insurance Agencies, a Dallas area firm ... County, is embarking on a six month charity event aimed at raising local support ... Cancer is one of the deadliest diseases in America; more than 7.5 million people ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... and conference coverage in veterinary medicine, will be launching its first bi-monthly issue ... health and medicine, business and practice management, and One Health. , In ...
(Date:2/21/2017)... ... February 21, 2017 , ... Each February ... History Month (officially African American History Month ). This month-long ... of a diverse race of people, but also the opportunity to examine the ...
(Date:2/21/2017)... California (PRWEB) , ... February 21, 2017 , ... ... world with over 50,000 participants. The connected care demonstration spanned multiple health ... the National Coordinator, roughly 30% of providers have no Health Information Exchange outside ...
Breaking Medicine News(10 mins):